Results 31 to 40 of about 268,751 (268)

Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma

Haematologica, 2010
Background The deregulation of several transcription factors contribute to the aggressive course of mantle cell lymphoma. This study focuses on survival signals emanating from the tumor environment and involving the signal transducer and activator of ...
Fanny Baran-Marszak, Mohand Boukhiar, Stéphanie Harel, Christelle Laguillier, Claudine Roger, Remy Gressin, Antoine Martin, Remi Fagard, Nadine Varin-Blank, Florence Ajchenbaum-Cymbalista, Dominique Ledoux   +10 more
doaj   +1 more source

Magnetic resonance imaging with pathological correlation in a case of mantle cell lymphoma of the parotid gland: a case report

Journal of Medical Case Reports, 2010
Introduction Mantle cell lymphoma is a rare non-Hodgkin's lymphoma. It is a subtype of B-cell lymphoma with frequent involvement of the bone marrow and the gastrointestinal tract. Isolated parotid gland involvement seldom occurs.
Karakozoglou Thrasivulos, Iordanidis Fotis, Athanasiadou Anastasia, Pilavaki Mayia, Palladas Panagiotis   +4 more
doaj   +1 more source

Mantle cell lymphoma of the larynx: Primary case report

Journal of Medical Case Reports, 2012
Introduction Primary laryngeal lymphomas are exceedingly rare. Only about a hundred cases have been reported. They consist mainly of non-Hodgkin lymphoma, especially of diffuse large B-cell lymphoma and mucosa-associated lymphoid tissue.
Naciri Sarah, Bennani-Baiti Anass A, Glaoui Meriem, Mouzount Houda, Ghanem Samia, Essakali Leila, Kzadri Mohamed, Errihani Hassan   +7 more
doaj   +1 more source

Multiple lymphomatous polyposis: A presentation for mantle cell lymphoma

Clinical Case Reports, 2020
Multiple lymphomatous polyposis is an uncommon presentation of mantle cell lymphoma, and when exhibited should prompt clinicians to incorporate mantle cell lymphoma into their differential workup.
Cory Gallivan, Ali Akbar
doaj   +1 more source

Mantle Cell Lymphoma

Archives of Pathology & Laboratory Medicine, 1999
Abstract Objective.—This article summarizes the most useful ancillary immunohistochemical and molecular assays for use in the diagnosis of mantle cell lymphoma. Data Sources.—The English language literature was surveyed, with an emphasis on recent publications, for articles presenting key advances in the molecular ...
Rebecca C. Hankin, Susan Hunter
openaire   +3 more sources

Interferon gamma inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma

Heliyon, 2019
IFI16, member of the IFN-inducible PYHIN-200 gene family, modulates proliferation, survival and differentiation of different cell lineages. In particular, IFI16 expression, which is regulated during the differentiation of B cells, was recently studied in
Pier Paolo Piccaluga, Mohsen Navari, Axel Visani, Flavia Rigotti, Claudio Agostinelli, Simona Righi, Erica Diani, Marco Ligozzi, Maria Carelli, Cristina Ponti, Isabella Bon, Donato Zipeto, Santo Landolfo, Davide Gibellini   +13 more
doaj   +1 more source

A Rare Case of Severe Lactic Acidosis in a Patient With Mantle Cell Lymphoma

Journal of Investigative Medicine High Impact Case Reports, 2021
Lactic acidosis is an extremely rare paraneoplastic manifestation of hematological malignancies, and often carries an extremely poor prognosis. Mantle cell lymphoma is an aggressive and rare form of non-Hodgkin lymphoma.
Kok Hoe Chan MD, Laxminarayan Prabhakar MD, Omar Al-Radideh MD, Byron Okwesili MD, Gowthami Are MD, Hamid Shaaban MD   +5 more
doaj   +1 more source

Emerging therapies in mantle cell lymphoma

Journal of Hematology & Oncology, 2020
Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit, transplant ...
W. Hanel, N. Epperla
semanticscholar   +1 more source

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

Journal of Clinical Oncology, 2019
PURPOSE The BRIGHT study ( ClinicalTrials.gov identifier: NCT00877006) was initiated to compare the efficacy and safety of bendamustine plus rituximab (BR) with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or ...
I. Flinn, R. Van der Jagt, B. Kahl, P. Wood, T. Hawkins, D. Macdonald, D. Simpson, K. Kolibaba, S. Issa, Julie E. Chang, J. Trotman, D. Hallman, Ling Chen, J. Burke   +13 more
semanticscholar   +1 more source

Mantle cell lymphoma of the gastrointestinal tract presenting with multiple intussusceptions – case report and review of literature

World Journal of Surgical Oncology, 2009
Background Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node. Extra nodal involvement is present in the majority of cases,
Abo Stephen M, Cosgrove John M, Reed Mary, Parikh Nalini S, Constantine Radu, Kella Venkata KN, King Saundra   +6 more
doaj   +1 more source